Compare FSFG & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSFG | BWAY |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 337.9M |
| IPO Year | 2008 | 2019 |
| Metric | FSFG | BWAY |
|---|---|---|
| Price | $33.18 | $16.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $31.50 | $23.50 |
| AVG Volume (30 Days) | 13.7K | ★ 61.9K |
| Earning Date | 01-27-2026 | 11-11-2025 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | 67.68 | ★ 213.09 |
| EPS | ★ 3.32 | 0.13 |
| Revenue | ★ $84,223,000.00 | $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | ★ $9.97 | $51.24 |
| Revenue Growth | 23.11 | ★ 27.08 |
| 52 Week Low | $21.63 | $7.84 |
| 52 Week High | $33.35 | $18.18 |
| Indicator | FSFG | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 69.51 | 46.96 |
| Support Level | $32.86 | $15.97 |
| Resistance Level | $33.35 | $17.38 |
| Average True Range (ATR) | 0.42 | 0.65 |
| MACD | 0.12 | -0.12 |
| Stochastic Oscillator | 88.93 | 15.87 |
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.